Long-term efficacy of subtotal splenectomy due to portal hypertension in cirrhotic patients

BMC Surgery

Jianhua Zhao³  Tao Wang¹  Weihua Zhang⁴  Fengguo Jian⁵  Yongbo Xu³  Lei Wang²  Wei Han³  Haibo Chu³ 

[1] Department of Pathology, The 89th Hospital of People’s Liberation Army, Weifang 261021, China;Department of Postgraduate, Weifang Medical University, Weifang 261042, China;Center of General Surgery, The 89th Hospital of People’s Liberation Army, West Beigong Road 256, Weifang 261021, China;Department of General Surgery, Weifang Traditional Chinese Medicine Hospital, Weifang 261041, China;Department of General Surgery, Changyi People’s Hospital, Changyi 261300, China

关键词: Shunt;    Subtotal splenectomy;    Splenomegaly;    Portal hypertension;   

Others  :  1220820
DOI  :  10.1186/s12893-015-0077-2

 received in 2015-02-16, accepted in 2015-07-20,  发布年份 2015

【 摘 要 】

Background

Portal hypertension (PHT) requires invasive measures to prevent rupture and bleeding of esophagogastric varices; however, the long-term results of subtotal splenectomy plus fixation of the retrosternal omentum majus (SSFROM) have not been reported. Specifically, the advantages and disadvantages of surgery that preserves the spleen and the long-term hematologic effects have not been described.

Study design

Our studies relating to SSFROM commenced in February 1999. As of April 2014 we have performed 256 subtotal splenectomies The records of 65 patients with PHT who underwent SSFROM were reviewed retrospectively.

Results

Four patients died within 4 years of surgery, with a 4-year survival rate of 94 %; the 11-year survival rate was 60 %. Eleven patients (17 %) had re-bleeding from esophagogastric varices. The white blood cell and platelet counts were higher 6 and 11 years post-operatively compared with pre-operative values (P < 0.01). Portal venous diameter, portal venous flow volume, splenic artery flow volume, as well as splenic length, thickness, and average cross-sectional areas were shown to be significantly constricted or decreased (P < 0.01). The proportion of serum CD3+ T cells, CD4+ T cells, and CD8+ T cells was increased (P < 0.01), while the serum levels of macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor were significantly decreased (P < 0.01). There was no significant change in the serum levels of IgA, IgM, IgG, and Tuftsin (P > 0.05). DSA demonstrated that 15 cases formed collateral circulations between the portal vein and superior vena cava.

Conclusion

SSFROM provide long-term hemostasis for esophagogastric variceal bleeding in PHT and corrected hypersplenism. SSFROM is an effective treatment for patients with PHT in whom long-term survival is expected.

【 授权许可】

   
2015 Chu et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Wu J, Li Z, Wang Z, Han X, Ji F, Zhang WW. Surgical and endovascular treatment of severe complications secondary to noncirrhotic portal hypertension: experience of 56 cases. Ann Vasc Surg. 2013; 27(4):441-6.
• [2]Batista-Neto J, Tognetti LB, Ribeiro LT, Balwani Mdo C, Muritiba T, Alves EE. Evolutional profile of the esophageal varices after splenectomy associated with ligation of the left gastric vein and sclerotherapy in schistosomal portal hypertension. Arq Bras Cir Dig. 2013; 26(1):49-53.
• [3]Kim SJ, Oh SH, Jo JM, Kim KM. Experiences with endoscopic interventions for variceal bleeding children with portal hypertension: a single center study. Pediatr Gastroenterol Hepatol Nutr. 2013; 16(4):248-53.
• [4]Wolff M, Hirner A. Surgical treatment of portal hypertension. Zentralbl Chir. 2005; 130(3):238-45.
• [5]Huang FR, Chu HB, Pan RW, Sun XJ, Li PC, Li YL. Treatment for patients with portal hypertension who underwent subtotal splenectomy and fixation of substernal omentum majus. Chin J Hepatobiliary Surg. 2002; 8(9):564-5.
• [6]Burroughs AK, Thalheimer U. Hepatic venous pressure gradient in 2010: optimal measurement is key. Hepatology. 2010; 51(6):1894-6.
• [7]Kim MY, Baik SK. Pathophysiology of portal hypertension, what’s new? Korean J Gastroenterol. 2010; 56(3):129-34.
• [8]Huang HC, Wang SS, Lee JY, Chen YC, Lee FY, Lin HC et al.. Simvastatin effects on portal-systemic collaterals of portal hypertensive rats. J Gastroenterol Hepatol. 2010; 25(8):1401-9.
• [9]Chan CC, Tsai SC, Cheng LY, Lee FY, Lin HC. Hemodynamic assessment of the development of portal-systemic collaterals in portal hypertensive rats. Dig Dis Sci. 2011; 56(2):417-24.
• [10]Kim JN, Sohn KM, Kim MY, Suk KT, Jeong SW, Jung HE et al.. Relationship between the hepatic venous pressure gradient and first variceal hemorrhage in patients with cirrhosis: a multicenter retrospective study in Korea. Clin Mole Hepatol. 2012; 18(4):391-6.
• [11]Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014; 18:281-91.
• [12]Maruyama H, Yokosuka O. Pathophysiology of portal hypertension and esophageal varices. Int J Hepatol. 2012; 2012:895787.
• [13]Silva AR, Kriguer-Júnior RJ, Serigiolle LC, Gomes HM, Rodrigues DA, Leme PL. Increase in spleen volume of rats on experimental model of pre-hepatic portal hypertension. Arq Bras Cir Dig. 2013; 26(3):206-12.
• [14]Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. Liver Int. 2011; 31(2):146-62.
• [15]Tiani C, Garcia-Pras E, Mejias M, de Gottardi A, Berzigotti A, Bosch J et al.. Apelin signaling modulates splanchnic angiogencesis and portosystemi collateral vessel formation in rats with portal hypertension. J Hepatol. 2009; 50(2):296-305.
• [16]Lu YF, Li XQ, Han XY, Gong XG, Chang SW. Peripheral blood cell variations in cirrhotic portal hypertension patients with hypersplenism. Asian Pac J Trop Med. 2013; 6(8):663-6.
• [17]Jeker R. Hypersplenism. Ther Umsch. 2013; 70(3):152-6.
• [18]Warren WD, Zeppa R, Fomon JJ. Selective trans-splenic decompression of gastroesophageal varices by distal splenorenal shunt. Ann Surg. 1967; 166(3):437-55.
• [19]Ibrahim M, El-Mikkawy A, Mostafa I, Devière J. Endoscopic treatment of acute variceal hemorrhage by using hemostatic powder TC-325: a prospective pilot study. Gastrointest Endosc. 2013; 78(5):769-73.
• [20]Elwakil R, Reda MA, Abdelhakam SM, Ghoraba DM, Ibrahim WA. Causes and outcome of upper gastrointestinal bleeding in Emergency Endoscopy Unit of Ain Shams University Hospital. J Egypt Soc Parasitol. 2011; 41(2):455-67.
• [21]Puhl G, Gül S, Neuhaus P. Portosystemic shunt surgery between TIPS and liver transplantation. Chirurg. 2011; 82(10):898-905.
• [22]Orloff MJ, Orloff MS, Girard B, Orloff SL. Bleeding esophagogastric varices from extrahepatic portal hypertension: 40 years’ experience with portal-systemic shunt. J Am Coll Surg. 2002; 194(6):717-28.
• [23]Gajin P, Radević B, Nenezić D, Ilijevski N, Jesić-Vukićević R, Radak D. Distal splenorenal shunt with partial spleen resection. Srp Arh Celok Lek. 2007; 135(5–6):293-7.
• [24]Sretenovic ALJ, Perišić V, Krstić Z, Vujović D, Pavićević P, Stanisavljević D et al.. Warren shunt combined with partial splenectomy for children with extrahepatic portal hypertension, massive splenomegaly, and severe hypersplenism. Surg Today. 2013; 43(5):521-5.
• [25]Chu H, Liu X, Zhao J, Xu Y, Wang L, Wang T et al.. Subtotal splenectomy for splenomegaly in cirrhotic patients. Int J Clin Exp Pathol. 2014; 7(8):4981-90.
• [26]Chu HB, Zhang TG, Zhao JH, Jian FG, Xu YB, Wang T et al.. Assessment of immune cells and function of the residual spleen after subtotal splenectomy due to splenomegaly in cirrhotic patients. BMC Immunol. 2014; 15(1):42. BioMed Central Full Text
• [27]Hase R, Hirano S, Kondo S, Okushiba S, Morikawa T, Katoh H. Long-term efficacy of distal splenorenal shunt with splenopancreatic and gastric disconnection for esophagogastric varices in patients with idiopathic portal hypertension. World J Surg. 2005; 29(8):1034-6.
• [28]Harding DJ, Perera MT, Chen F, Olliff S, Tripathi D. Portal vein thrombosis in cirrhosis: Controversies and latest developments. World J Gastroenterol. 2015; 21(22):6769-84.
• [29]Lai W, Lu SC, Li GY, Li CY, Wu JS, Guo QL et al.. Anticoagulation therapy prevents portal-splenic vein thrombosis after splenectomy with gastroesophageal devascularization. World J Gastroenterol. 2012; 18(26):3443-50.
• [30]Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE et al.. Causes and consequences of portal vein thrombosis in 1243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015; 61(2):660-7.
• [31]Abdel-Razik A, Mousa N, Elhelaly R, Tawfik A. De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system. Eur J Gastroenterol Hepatol. 2015; 27(5):585-92.
• [32]Sun L, Zhou H, Gu L, Jiang C, Liu Y, Xu Q. Effects of surgical procedures on the occurrence and development of postoperative portal vein thrombosis in patients with cirrhosis complicated by portal hypertension. Int J Surg. 2015; 16(Pt A):31-5.